How does ACARIX's PB Ratio compare to its peers?

ACARIX is expensive based on its Price-To-Book Ratio (5.3x) compared to the peer average (1.8x).

How does ACARIX's PB Ratio compare vs other companies in the SE Medical Equipment Industry?

ACARIX is expensive based on its Price-To-Book Ratio (5.3x) compared to the Swedish Medical Equipment industry average (2.3x).

What is ACARIX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ACARIX's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of ACARIX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ACARIX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Acarix (OM:ACARIX) - Stock Price, News & Analysis

ACARIX Stock Overview

A medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. More details

ACARIX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 110.35% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK6M)

Highly volatile share price over the past 3 months compared to the Swedish market

Does not have a meaningful market cap (SEK341M)

Has less than 1 year of cash runway

+ 1 more risk

Acarix AB (publ) Competitors

BrainCool

OM:BRAIN

SEK 408.0m

Boule Diagnostics

OM:BOUL

SEK 264.8m

Integrum

OM:INTEG B

SEK 446.1m

Careium

OM:CARE

SEK 698.2m

Price History & Performance

Summary of all time highs, changes and price drops for Acarix
Historical stock prices
Current Share Price	SEK 0.32
52 Week High	SEK 0.60
52 Week Low	SEK 0.17
Beta	1.48
11 Month Change	-2.28%
3 Month Change	4.38%
1 Year Change	47.82%
33 Year Change	-64.86%
5 Year Change	-82.09%
Change since IPO	-98.03%

Recent updates

Shareholder Returns

	ACARIX	SE Medical Equipment	SE Market
7D	-2.1%	-4.1%	-2.1%
1Y	47.8%	-9.7%	10.8%

Return vs Industry: ACARIX exceeded the Swedish Medical Equipment industry which returned -9.7% over the past year.

Return vs Market: ACARIX exceeded the Swedish Market which returned 10.8% over the past year.

Price Volatility

Is ACARIX's price volatile compared to industry and market?
ACARIX volatility
ACARIX Average Weekly Movement	13.2%
Medical Equipment Industry Average Movement	7.5%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: ACARIX's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: ACARIX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2009	14	Aamir Mahmood	www.acarix.com

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States.

Acarix AB (publ) Fundamentals Summary

How do Acarix's earnings and revenue compare to its market cap?
ACARIX fundamental statistics
Market cap	SEK 339.30m
Earnings (TTM)	-SEK 72.23m
Revenue (TTM)	SEK 5.68m

60.0x

P/S Ratio

-4.7x

P/E Ratio

Is ACARIX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACARIX income statement (TTM)
Revenue	SEK 5.68m
Cost of Revenue	SEK 550.00k
Gross Profit	SEK 5.13m
Other Expenses	SEK 77.36m
Earnings	-SEK 72.23m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)	-0.068
Gross Margin	90.31%
Net Profit Margin	-1,272.33%
Debt/Equity Ratio	0%

How did ACARIX perform over the long term?

See historical performance and comparison

ACARIX Stock Overview

Rewards

Risk Analysis

Acarix AB (publ) Competitors

OM:BRAIN

SEK 408.0m

OM:BOUL

SEK 264.8m

OM:INTEG B

SEK 446.1m

OM:CARE

SEK 698.2m

Price History & Performance

Recent News & Updates

Acarix AB (publ), Annual General Meeting, May 15, 2025

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: kr0.019 loss per share (vs kr0.038 loss in 3Q 2023)

New major risk - Share price stability

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023)

Recent updates

Acarix AB (publ), Annual General Meeting, May 15, 2025

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: kr0.019 loss per share (vs kr0.038 loss in 3Q 2023)

New major risk - Share price stability

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023)

Acarix Expands Within US Wellness Exam Market

Acarix AB (publ) announced that it expects to receive SEK 21 million in funding

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023)

Acarix AB (publ) Approves Board Elections

Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022)

Acarix Appoints New Members to the Advisory Board

New major risk - Share price stability

Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network

New major risk - Financial position

Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022)

Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.

Price target increased by 18% to kr0.90

Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022)

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023

Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024

Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial

Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021)

Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr2.60

No independent directors

Acarix AB (publ), Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis

Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System

Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020)

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020)

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Director has left the company

Director has left the company

Director has left the company

Chairman of the Board Werner Braun has left the company

First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020)

Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019)

Director recently bought kr890k worth of stock